Skip to content

Study · Systematic review · 2024

10 results

Efficacy and safety of oral semaglutide in type 2 diabetes: A systematic review of real-world evidence.

Singh AK, Singh R, Singh A, Misra A

Diabetes & metabolic syndrome1 May 2024Cited by 13 (Europe PMC)

PMID38718449 (opens in a new tab)DOI10.1016/j.dsx.2024.103024 (opens in a new tab)PepBankPUB-38718449
Publisher pagePubMedAsk about this study
Jump to 10 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

10 results from studies that gave the peptide. 10 results from people.

  1. 01HumanSystematic reviewEfficacy outcome

    In prospective real-world studies of oral semaglutide in type 2 diabetes, HbA1c reduction varied from -0.9 % to -1.6 %.

    In plain wordsIn real-world studies that followed people forward, oral semaglutide lowered HbA1c by 0.9 to 1.6 percentage points.

    Peptide
    Semaglutide
    Outcome
    DecreaseHbA1c reduction, prospective studies
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · oralAs given in this study (human).

    Source sentences

    Summary
    In prospective studies, the primary outcome of HbA1c reduction varied from -0.9 % to -1.6 %
    1 context sentence
    Summary · context
    To date, results from four prospective and ten retrospective real-world studies of oral semaglutide in T2D are available.
  2. 02HumanSystematic reviewEfficacy outcome

    In prospective real-world studies of oral semaglutide in type 2 diabetes, weight loss varied from -4.7 kg to -8.2 kg.

    In plain wordsIn real-world studies that followed people forward, oral semaglutide led to weight loss of 4.7 to 8.2 kg.

    Peptide
    Semaglutide
    Outcome
    DecreaseWeight loss, prospective studies
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · oralAs given in this study (human).

    Source sentences

    Summary
    weight loss varied from -4.7 kg to -8.2 kg
    1 context sentence
    Summary · context
    To date, results from four prospective and ten retrospective real-world studies of oral semaglutide in T2D are available.
  3. 03HumanSystematic reviewEfficacy outcome

    In prospective real-world studies of oral semaglutide in type 2 diabetes, the HbA1c target of <7 % was achieved in 30 %-64 %.

    In plain wordsIn real-world studies that followed people forward, 30% to 64% of people on oral semaglutide reached an HbA1c below 7%.

    Peptide
    Semaglutide
    Outcome
    IncreaseHbA1c below 7 %, prospective studies
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · oralAs given in this study (human).

    Source sentences

    Summary
    HbA1c target of <7 % was achieved in 30 %-64 % with oral semaglutide.
    1 context sentence
    Summary · context
    To date, results from four prospective and ten retrospective real-world studies of oral semaglutide in T2D are available.
  4. 04HumanSystematic reviewEfficacy outcome

    In retrospective real-world studies of oral semaglutide in type 2 diabetes, HbA1c reduction varied from -0.4 % to -1.8 %.

    In plain wordsIn real-world studies that looked back at records, oral semaglutide lowered HbA1c by 0.4 to 1.8 percentage points.

    Peptide
    Semaglutide
    Outcome
    DecreaseHbA1c reduction, retrospective studies
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · oralAs given in this study (human).

    Source sentences

    Summary
    In retrospective studies, HbA1c reduction varied from -0.4 % to -1.8 %
    1 context sentence
    Summary · context
    To date, results from four prospective and ten retrospective real-world studies of oral semaglutide in T2D are available.
  5. 05HumanSystematic reviewEfficacy outcome

    In retrospective real-world studies of oral semaglutide in type 2 diabetes, weight reduction varied from -1.4 to -9.0 kg.

    In plain wordsIn real-world studies that looked back at records, oral semaglutide led to weight loss of 1.4 to 9.0 kg.

    Peptide
    Semaglutide
    Outcome
    DecreaseWeight reduction, retrospective studies
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · oralAs given in this study (human).

    Source sentences

    Summary
    weight reduction varied from -1.4 to -9.0 kg
    1 context sentence
    Summary · context
    To date, results from four prospective and ten retrospective real-world studies of oral semaglutide in T2D are available.
  6. 06HumanSystematic reviewEfficacy outcome

    In retrospective real-world studies of oral semaglutide in type 2 diabetes, the HbA1c target of <7 % was achieved in 32-64 %.

    In plain wordsIn real-world studies that looked back at records, 32% to 64% of people on oral semaglutide reached an HbA1c below 7%.

    Peptide
    Semaglutide
    Outcome
    IncreaseHbA1c below 7 %, retrospective studies
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · oralAs given in this study (human).

    Source sentences

    Summary
    HbA1c target of <7 % was achieved in 32-64 %
    1 context sentence
    Summary · context
    To date, results from four prospective and ten retrospective real-world studies of oral semaglutide in T2D are available.
  7. 07HumanSystematic reviewEfficacy outcome

    In retrospective real-world studies of oral semaglutide, 30-41 % of people with type 2 diabetes had 5 % or more weight loss.

    In plain wordsIn real-world studies that looked back at records, 30% to 41% of people on oral semaglutide lost at least 5% of body weight.

    Peptide
    Semaglutide
    Outcome
    IncreaseWeight loss of 5 % or more, retrospective studies
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · oralAs given in this study (human).

    Source sentences

    Summary
    30-41 % of people with T2D had ≥5 % weight loss with oral semaglutide.
    1 context sentence
    Summary · context
    To date, results from four prospective and ten retrospective real-world studies of oral semaglutide in T2D are available.
  8. 08HumanSystematic reviewSafety outcome

    In prospective real-world studies, gastrointestinal adverse events with oral semaglutide varied from 16 % to 50 %.

    In plain wordsIn real-world studies that followed people forward, 16% to 50% had stomach or gut side effects with oral semaglutide.

    Peptide
    Semaglutide
    Outcome
    Not applicableGastrointestinal adverse events, prospective studies
    Study

    n: not reported in source

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    Dose not stated · oralAs given in this study (human).

    Source sentences

    Summary
    Gastrointestinal adverse events with oral semaglutide varied from 16 % to 50 % in prospective
    1 context sentence
    Summary · context
    To date, results from four prospective and ten retrospective real-world studies of oral semaglutide in T2D are available.
  9. 09HumanSystematic reviewSafety outcome

    In retrospective real-world studies, gastrointestinal adverse events with oral semaglutide varied from 6 % to 47 %.

    In plain wordsIn real-world studies that looked back at records, 6% to 47% had stomach or gut side effects with oral semaglutide.

    Peptide
    Semaglutide
    Outcome
    Not applicableGastrointestinal adverse events, retrospective studies
    Study

    n: not reported in source

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    Dose not stated · oralAs given in this study (human).

    Source sentences

    Summary
    6 %-47 % in retrospective RWS.
    1 context sentence
    Summary · context
    To date, results from four prospective and ten retrospective real-world studies of oral semaglutide in T2D are available.
  10. 10HumanSystematic reviewSafety outcome

    Overall, 0 %-18 % of patients in real-world studies discontinued oral semaglutide due to any cause.

    In plain wordsIn real-world studies, 0% to 18% of people stopped taking oral semaglutide for any reason.

    Peptide
    Semaglutide
    Outcome
    Not applicableDiscontinuation due to any cause
    Study

    n: not reported in source

    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated · oralAs given in this study (human).

    Source sentences

    Summary
    Overall, 0 %-18 % of patients had oral semaglutide discontinuation due to any cause.
    1 context sentence
    Summary · context
    To date, results from four prospective and ten retrospective real-world studies of oral semaglutide in T2D are available.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.